METFORMIN 500mg. IP + GLICLAZIDE 80mg. IP

An antidiabetic agent that prevents blood glucose levels from rising to very high levels. Stimulates the pancreas gland to produce more insulin hormone which lowers blood glucose. Improves defective insulin secretion in type 2 diabetes patients. An effective treatment for patients having inadequately controlled on sulfonylurea or metformin alone. (Anil Pareek, 2010) Improves glycemic control in patients with type 2 diabetes insufficiently controlled by first-line monotherapy. (Ulrike Gottwald-Hostalek, 2016) Aids prevent serious complications of diabetes such as diabetic neuropathy, diabetic retinopathy, diabetic neuropathy. Possesses the properties of preventing the progression of diabetic retinopathy and of controlling blood glucose levels. (Y Akanuma, 1988) Synergistically improves the fasting blood glucose and lowers glycosylated hemoglobin (HbA1c) level in type 2 diabetic patients. (Mansour Alsharidah, 2018) A beneficial therapy that safeguards against complications of diabetic Mellitus. (Mansour Alsharidah M. A.-M.-M., 2018) A suitable treatment option that provides better blood glucose control for patients with Type 2 diabetes. (H Y Cho, 2009) Significantly improves blood glucose control in type 2 diabetic patients, notably in the elderly and in patients with impaired renal function. (P Drouin, 2004) Achieves good glycemic control and improves lipid levels with a better tolerability profile. (Anil Pareek, 2010) An effective and tolerable agent for the management of type 2 diabetes mellitus. (Nareen Krishna Polavarapu, 2020) Provides significantly greater glycated hemoglobin, fasting plasma glucose, and postprandial glucose reductions as compared to rosiglitazone plus metformin. (Ulrike Gottwald-Hostalek J. S., 2016)